http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
새로운 beta-lactam계 항생물질 개발을 위한 검정용 균주의 개발
김대진(Dae Jin Kim),최금화(Keum Hwa Choi),김숙경(Sook Kyung Kim),최성숙(Sung Sook Choi),김병각(Byung Kak Kim),강창율(Chang Yuil Kang),최응칠(Eung Chil Choi) 대한약학회 1995 약학회지 Vol.39 No.2
Clinically isolated bacterial strains resistant to almost of all the clinically superior beta-lactam antibiotics can be used to screen the promising ones among the newly synthesized beta-lactam antibiotics. To select the resistant strains, the susceptibility of 389 strains of S. aureus, 144 strains of coagulase negative staphylococci, 509 strains of E. coli, 115 strains of E. cloacae and 187 strains of P. aeruginosa to methicillin, ampicillin, piperacillin and gentamicin was determined. The susceptibility of 19 bacterial strains selected through the first screening to cefixime, cefotiam, cefotaxime, flomoxef, cepfirome, cefdnir, SCE-2787, panipenem and imipenem was determined. Four strains of S. aureus finally selected have high degree of resistance to almost of all bata-lactam antibiotics used and also produce beta-lactamases. These 4 strains of S. aurues can be used to screen effectively the promising beta-lactam antibiotics among the numerous numbers of the newly synthesized beta-lactam antibiotics.
Studies on Protoplast Formation and Regeneration of Ganoderma lucidum
Choi, Seung-Hee,Kim, Byong-Kak,Kim, Ha-Won,Kwak, Jin-Hwan,Park, Eung-Chil,Kim, Young-Choong,Yoo, Young-Bok,Park, Yong-Hwan The Pharmaceutical Society of Korea 1987 Archives of Pharmacal Research Vol.10 No.3
To obtain a new strain of Ganoderma lucidum by protoplast fusion technique, its protoplast formation and regeneration were studied. Several factors affecting the protoplast formation and regeneration were investigated to find their optimum conditions. The mycelium was grown for four days on the cellophane membrane placed on G. Incidum complete medium (GCM). When various commercial lytic enzymes were examined for protoplast isolation, the combination of Novozym 234 and $\beta$glucuronidase was found to be effective. An osmotic stabilizer, 0.6 M sucrose in 20 mM phosphate buffer pH 5.8, gave the highest yield of protoplasts. Three-hour incubation in shaking incubator was most suitable for releasing protoplasts. To increase the protoplast yield, pretreatment with 2-mercaptoethanol was carried out. The regeneration frequency in GCM containing 0.6M MgSO$_4$ 7$H_2O$ was shown to be 0.66%.
( Seung Kak Shin ),( Oh Sang Kwon ),( Chang Hwi Yoon ),( Young-joo Jin ),( Jin-woo Lee ),( Sangheun Lee ),( Ki Jun Han ),( Young Nam Kim ),( Tae Hun Kim ),( Yun Soo Kim ),( Duck Joo Choi ),( Ju Hyun K 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Combination of daclatasvir (DCV) and asunaprevir (ASV) has been approved in Korea for the treatment of genotype 1b (GT1b) hepatitis C virus (HCV) infected patients. The efficacy in virologic response, improvement of liver function and non-invasive fibrosis marker in liver cirrhosis (LC) were investigated. Methods: All HCV GT1b patients who were treated with DCV and ASV for at least 4 weeks from August 2015 to January 2017, were retrospectively enrolled. Virologic response was measured at 4 weeks (rapid virologic response, RVR), at 24 weeks (end of treatment response, ETR), and at 12 weeks after the end of treatment (sustained virologic response, SVR12). Liver function, aspartate transaminase to platelet ratio index (APRI), FIB-4 index, and fibrosis index (FI) were compared between before and after treatment (SVR12). Results: Patients with GT1b patients (n=474) were examined for resistance associated variants (RAVs). Sixty-seven patients had RAV. A total of 290 RAV-negative patients were treated with DCV and ASV for at least 4 weeks. Baseline characteristics were obtained: age (54±11 years), gender (male: 50.3%), LC (29.0%), treatment-naïve (74.8%), ALT (58.5±49.2 IU/L), HCV RNA (1,915,001±4,969,456 IU/mL). RVR (255/277, 92.1%), ETR (190/195, 97.4%), and SVR (146/152, 96.1%) rates were obtained. SVR rates were not significantly different between non-LC (102/104, 98.1%) and LC patients (44/48, 91.7%) (p=0.080). SVR rates were not significantly different between treatment- naïve (103/106, 97.2%) and treatment-experienced patients (43/46, 93.5%) (p=0.368). In LC patients (n=48), there were significant changes of albumin (3.8±0.8 to 4.0±0.5 g/dL, p=0.036), platelet count (109.6±52.6 to 120.3±58.5 x103/mm3, p=0.004), APRI (2.6±3.1 to 0.8±0.6, p=0.001), FIB-4 (7.6±6.5 to 2.9±1.6, p<0.001), and FI (3.1±1.1 to 2.9±1.2, p=0.058) after treatment. Conclusions: DCV and ASV treatment for HCV GT1b infected Korean subjects without RAV achieved high SVR rates. In addition, improvement of liver function and non-invasive fibrosis marker were noted in patients with LC.
토양균의 α-amylase 저해제 검색 및 분리에 관한 연구(제1보) : Streptomyces DMC -225 균주의 저해 성분의 분리 및 작용
곽진환(Jin Hwan Kwak),서병석(Byung Suk Su),최응칠(Eung Chil Choi),김병각(Byong Kak Kim) 한국생약학회 1985 생약학회지 Vol.16 No.1
To find amylase inhibitors produced by microorganisms from soils, a strain which had a strong inhibitory activity against bacterial α-amylase was isolated from the soil sample collected in Seoul. The morphological and physiological characteristics of this strain on several media and its utilization of carban sources showed that it was one of Streptomyces species according to the International Streptomyces Project method. The amylase inhibitor of this strain was purified by means of acetone precipitation, adsorption on Amberlite XAD-2, and column chromatography on Amberlite CG-50 and SP-sephadex C-25. The inhibitor was stable at the pH range of 1-10 and at 100℃ for half an hour, and had inhibitory activities against other amylases such as salivary α-amylase, pancreatic α-amylase, fungal α-amylase and glucoamylase.The kinetic studies of the inhibitor showed that its inhibitory effect on starch hydrolysis by α-amylase was non-competitive.